Overview

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-03-14
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca